The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Centessa Pharmaceuticals plc shares valued at $23,970 were sold by YVER ANTOINE on Mar 01. At $3.42 per share, YVER ANTOINE sold 7,000 shares. The insider’s holdings dropped to 806,681 shares worth approximately $3.23 million following the completion of this transaction.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Also, YVER ANTOINE sold 7,700 shares, netting a total of over 29,201 in proceeds. Following the sale of shares at $3.79 each, the insider now holds 813,681 shares.
Before that, YVER ANTOINE had sold 6,970 shares from its account. In a trade valued at $22,136, the EVP & Chairman of Development traded Centessa Pharmaceuticals plc shares for $3.18 each. Upon closing the transaction, the insider’s holdings decreased to 6,970 shares, worth approximately $3.01 million.
As published in a research note from Morgan Stanley on August 12, 2022, Centessa Pharmaceuticals plc [CNTA] has been rated down from an Overweight to an Underweight and the price target has been revised to $5 from $10. This represents a 20.0% premium over Thursday’s closing price. Analysts at BMO Capital Markets started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid June. As of June 03, 2022, Jefferies has decreased its “Buy” rating to a “Hold” for CNTA. Earlier on February 11, 2022, Goldman initiated its rating. Their recommendation was “a Neutral” for CNTA stock.
Analyzing CNTA Stock Performance
On Thursday, Centessa Pharmaceuticals plc [NASDAQ: CNTA] rose 3.36% to $4.00. The stock’s lowest price that day was $3.56, but it reached a high of $4.01 in the same session. During the last five days, there has been a surge of approximately 3.63%. Over the course of the year, Centessa Pharmaceuticals plc shares have jumped approximately 29.03%. Shares of the company reached a 52-week high of $4.05 on 01/26/23 and a 52-week low of $3.00 on 02/21/23. A 50-day SMA is recorded $3.63, while a 200-day SMA reached $4.02. Nevertheless, trading volume fell to 0.61 million shares from 40100.0 shares the previous day.
Support And Resistance Levels for Centessa Pharmaceuticals plc (CNTA)
According to the 24-hour chart, there is a support level at 3.70, which, if violated, would cause prices to drop to 3.41. In the upper region, resistance lies at 4.15. The next price resistance is at 4.31. RSI (Relative Strength Index) is 61.06 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.19, which suggests the price will decrease in the coming days. Percent R is at 1.02%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
Is Centessa Pharmaceuticals plc subject to short interest?
Stocks of Centessa Pharmaceuticals plc saw a sharp rise in short interest on Jan 30, 2023 jumping by 50000.0 shares to 1.82 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 1.77 million shares. A jump of 2.75% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.38 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.38.
Which companies own the most shares of Centessa Pharmaceuticals plc (CNTA)?
According to BVF Partners LP filings, the company currently owns 6,894,345 shares, which is about 7.29% of the total CNTA shares outstanding. With the completion of the buy transaction, EcoR1 Capital, LLC’s stake is now worth $18,417,622. T. Rowe Price Associates, Inc. reduced a -2.40% interest valued at $8.4 million while Janus Henderson Investors US LLC sold a -830,437 stake. A total of 1,878,383 shares of Centessa Pharmaceuticals plc were sold by Tanager Wealth Management LLP during the quarter, and 522,118 were bought by Fidelity Management & Research Co. In its current portfolio, Franklin Advisers, Inc. holds 832,348 shares valued at $2.93 million.